Intuitive Surgical, Inc. (ISRG) has been a trending stock, outperforming the broader market with shares rising 10.1% over the past month compared to the S&P 500's 1% gain. The company recently reported quarterly revenues of $2.89 billion, beating the consensus estimate of $2.81 billion by 3.08%, while EPS of $2.8 exceeded expectations by 12.9%. This performance marks the fourth consecutive quarter where ISRG beat earnings estimates and the third time topping revenue forecasts in the trailing four quarters.
Analysts maintain a strong outlook for Intuitive Surgical, with consensus earnings projections showing significant growth. For the current quarter, expected EPS is $2.61, representing an 8.8% increase year-over-year. Full-year consensus estimates stand at $10.74 (up 20.3%), while the next fiscal year projects $11.98 in earnings (an 11.6% rise). Revenue growth is also robust, with full-year and next-year sales estimates of $11.74 billion and $13.21 billion respectively, indicating sustained expansion.
Despite its strong operational performance and a Zacks Rank #2 (Buy) rating suggesting near-term outperformance, Intuitive Surgical faces valuation concerns. The company is graded an F on the Zacks Value Style Score, indicating it trades at a premium relative to its peers based on traditional metrics like P/E and P/S ratios. While the high valuation suggests the market prices in significant growth potential, the stock's fair value remains tied to future earnings revisions and sustained revenue expansion.
📈 ISRG shares rose 10.1% last month, outperforming S&P 500 by 9.1%.
💰 Quarterly revenue hit $2.89B, beating estimates by 3.08%.
📊 EPS beat expectations by 12.9%, marking fourth consecutive quarter of beats.
🔭 Analysts project current quarter EPS of $2.61, an 8.8% year-over-year increase.
⚠️ Stock trades at a premium to peers with a Zacks Value Style Score of F.
📈 ISRG shares gained 10.1% over the past month, significantly outperforming the S&P 500 composite which rose only 1%.
💰 The company reported quarterly revenues of $2.89 billion, surpassing analyst consensus estimates by 3.08%.
📊 Intuitive Surgical beat EPS expectations by 12.9% in the last quarter, marking a fourth consecutive quarter of earnings beats.
🔭 Analysts project current quarter EPS of $2.61, reflecting an 8.8% year-over-year increase.
🚀 Full-year consensus earnings estimates for ISRG are set at $10.74, indicating a 20.3% growth from the prior year.
💼 Revenue guidance remains strong with full-year sales estimates of $11.74 billion and next-year projections of $13.21 billion.
🏆 The stock holds a Zacks Rank #2 (Buy) based on positive trends in earnings estimate revisions.
⚠️ ISRG is graded an F on the Zacks Value Style Score, signaling it trades at a premium to its peers.
Bullish Signals
Shares rose 10.1% last month, beating S&P 500.
Risk Factors
Graded F on Zacks Value Style Score due to premium valuation.
High valuation risks sensitivity to earnings or revenue slowdowns.
Bullish Signals
Shares returned +10.1% over the past month, significantly outperforming the S&P 500 composite's +1% gain.
The company beat consensus EPS estimates by +12.9% and revenue estimates by +3.08% in the last reported quarter.
Intuitive Surgical has beaten earnings estimates for four consecutive trailing quarters and topped revenue estimates three times during that period.
Analysts project current quarter EPS of $2.61, representing an 8.8% increase from the year-ago quarter.
Full-year consensus earnings estimate of $10.74 points to a +20.3% change from the prior year.
Revenue estimates for the current and next fiscal years are $11.74 billion and $13.21 billion, indicating +16.7% and +12.5% growth respectively.
The stock is assigned a Zacks Rank #2 (Buy), suggesting it may outperform the broader market in the near term.
Risk Factors
Intuitive Surgical is graded an F on the Zacks Value Style Score, indicating it is trading at a premium to its peers based on valuation multiples.
The high valuation suggests the stock price may be sensitive to any slowdown in future earnings growth or revenue expansion.
Intuitive Surgical (NASDAQ:ISRG) reported strong fiscal Q2 results with revenue increasing 19% year-over-year to $2.89 billion, driven by a 15% rise in worldwide da Vinci procedure volumes. The company's recurring revenue model proved resilient as instruments and accessories revenue grew 18% to $1.73 billion, reflecting the compounding value of its expanding installed base which reached 11,710 systems.
Management provided forward-looking guidance expecting procedure growth between 13.5% and 15.5% for fiscal 2026, with a target to land near the midpoint of that range. However, Intuitive faces margin headwinds from tariffs, anticipating a non-GAAP gross margin decline to 68-69% in 2026 due to an estimated one-percentage-point tariff impact, with warnings that additional tariffs could materially affect results.
The article contrasts Intuitive's growth trajectory against Gilead Sciences, noting that while Intuitive relies on sustaining its high-growth engine amidst cost pressures, Gilead faces portfolio concentration risks despite strong HIV franchise performance. Analysts highlight the strategic divergence where Intuitive must maintain mid-teens procedure growth rates as the business scales, whereas Gilead seeks diversification beyond its dominant HIV segment.
Intuitive Surgical placed 468 da Vinci systems in the quarter, including 246 units of the newer da Vinci 5 model. The company's non-GAAP EPS reached $2.80 compared to $2.19 a year earlier, demonstrating profitability growth alongside revenue expansion. Investors are weighing the risk-adjusted upside of Intuitive's established growth machine against the potential for continued high-level execution required to sustain its market position.
📈 ISRG Q2 revenue grew 19% YoY to $2.89B driven by da Vinci volume increases.
🔧 Instruments revenue rose 18% to $1.73B validating recurring model on 11,710 systems.
📅 Management forecasts 13.5%-15.5% procedure growth for fiscal 2026 near midpoint target.
⚠️ Non-GAAP margins expected to fall to 68-69% in 2026 due to tariff costs.
💰 Non-GAAP EPS reached $2.80, up from $2.19 a year earlier in Q2.
📈 Intuitive Surgical reported fiscal Q2 revenue growth of 19% year-over-year, reaching $2.89 billion driven by a 15% increase in worldwide da Vinci procedure volumes.
🔧 Instruments and accessories revenue increased 18% to $1.73 billion, validating the company's recurring revenue model based on its expanding installed base of 11,710 systems.
📅 Management expects worldwide da Vinci procedure growth between 13.5% and 15.5% for fiscal 2026, targeting a result near the midpoint of that range.
⚠️ The company anticipates non-GAAP gross margins falling to 68-69% in 2026 due to an estimated one-percentage-point tariff impact on costs.
🏭 Intuitive placed 468 da Vinci systems during the quarter, with 246 units being the newer da Vinci 5 model, contributing to a 12% increase in the global installed base.
💰 Non-GAAP EPS reached $2.80 in fiscal Q2, representing significant growth compared to $2.19 reported a year earlier.
📉 Cell Therapy sales declined 14% to $417 million amid competitive headwinds, though this segment is less central to Intuitive's core robotics business than Gilead's HIV focus.
🤖 The da Vinci installed base continues to compound value, as more systems support additional procedures which in turn drive demand for consumables and services.
📊 Management cautioned that tariffs beyond current assumptions could materially affect 2026 financial results, introducing external cost risks to the growth trajectory.
Bullish Signals
Revenue grew 19% YoY driven by expanding procedure volumes.
Risk Factors
Non-GAAP gross margins expected to decline to 68-69% in fiscal 2026.
Additional tariffs could materially affect 2026 financial results.
Worldwide da Vinci procedure growth slowed to 15% in Q2.
Bullish Signals
Intuitive Surgical achieved a 19% year-over-year revenue increase in fiscal Q2, demonstrating robust top-line growth driven by expanding procedure volumes.
The company successfully placed 468 da Vinci systems in the quarter, growing its global installed base to 11,710 units and reinforcing its recurring revenue model.
Non-GAAP EPS grew significantly to $2.80 from $2.19 a year earlier, indicating strong profitability alongside revenue expansion.
Instruments and accessories revenue rose 18% to $1.73 billion, confirming the compounding value of the installed base as procedures increase.
Management raised expectations for procedure growth in fiscal 2026, targeting a range of 13.5% to 15.5% with a specific aim to hit the midpoint.
Risk Factors
The company expects non-GAAP gross margins to decline to 68-69% in fiscal 2026 due to an estimated one-percentage-point impact from tariffs.
Management explicitly warned that additional tariffs beyond current assumptions could materially affect the company's 2026 financial results.
Worldwide da Vinci procedure growth slowed slightly to approximately 15% in fiscal Q2 compared to 17% a year earlier, indicating potential deceleration as the business scales.
Intuitive Surgical reported robust financial performance for the second quarter of 2026, generating USD 2.89 billion in revenue. This figure represents an 18.5 percent increase compared to the same period in the prior year and exceeded analyst estimates by 2.6 percent, indicating strong commercial execution despite a measured market reaction.
Operating efficiency improved sequentially during this period, with operating margins expanding from 31 percent in Q1 2026 to 34 percent in Q2 2026. Diluted earnings per share also saw a slight increase, rising from USD 2.28 to USD 2.29 over the same periods, reflecting the company's ability to maintain profitability while scaling revenue.
Despite the positive fundamental results, Intuitive Surgical's stock price closed at USD 398.30 on September 23, 2026, which was down 0.94 percent for the session and remained 34.05 percent below its 52-week high of USD 603.88. The market capitalization stood at approximately USD 140.7 billion, suggesting that investors are weighing current growth against valuation levels and future procedure volume expectations.
The company continues to focus on recurring revenue streams from instruments and system placements as key drivers for future updates. While a meta-analysis of da Vinci surgery outcomes supports its medical technology positioning, the immediate stock factor remains the commercial growth trajectory demonstrated by the double-digit revenue expansion.
📈 ISRG Q2 2026 revenue hit USD 2.89B, up 18.5% year-over-year.
🎯 Company beat estimates by 2.6%, confirming strong commercial growth.
💰 Operating margins expanded sequentially to 34% in Q2 2026.
📊 Diluted EPS rose from USD 2.28 to USD 2.29.
🏢 Market cap stood at USD 140.7B as of Sept 23, 2026.
📈 Intuitive Surgical generated USD 2.89 billion in Q2 2026 revenue, marking an 18.5 percent year-over-year increase.
🎯 The company beat analyst estimates by 2.6 percent, reinforcing the strength of its commercial growth story.
💰 Operating margins expanded sequentially to 34 percent in Q2 2026, up from 31 percent in the previous quarter.
📊 Diluted earnings per share rose from USD 2.28 to USD 2.29 between Q1 and Q2 2026.
📉 The stock closed at USD 398.30, trading 34.05 percent below its 52-week high of USD 603.88.
🏢 Intuitive Surgical maintained a market capitalization of approximately USD 140.7 billion as of September 23, 2026.
🔍 The company released a meta-analysis on da Vinci surgery outcomes to support its medical technology positioning.
Bullish Signals
Revenue grew 18.5% YoY to $2.89B in Q2 2026.
Beat estimates by 2.6%, exceeding market expectations.
Operating margins rose sequentially to 34% in Q2.
EPS increased from $2.28 to $2.29.
Risk Factors
Stock trades 34.05% below 52-week high.
Shares fell 0.94% on earnings release.
Bullish Signals
Intuitive Surgical delivered USD 2.89 billion in Q2 2026 revenue, representing an impressive 18.5 percent year-over-year growth.
The company beat analyst estimates by 2.6 percent, demonstrating that its financial performance exceeds market expectations.
Operating margins improved sequentially to 34 percent in Q2 2026, indicating enhanced operational efficiency and profitability.
Diluted earnings per share increased from USD 2.28 to USD 2.29, showing consistent profit generation alongside revenue growth.
Risk Factors
The stock price remains significantly undervalued relative to its potential, trading 34.05 percent below its 52-week high despite strong fundamentals.
The market reaction was measured with a 0.94 percent decline on the day of the earnings release, suggesting cautious investor sentiment regarding current valuation levels.
The article highlights a divergence in performance trends between Intuitive Surgical (ISRG) and Abbott Laboratories, noting that while the latter faces challenges, ISRG continues to demonstrate robust financial expansion. Specifically, Intuitive Surgical has achieved a significant revenue growth rate of 45%, indicating strong demand for its surgical robotics platforms and continued market penetration.
Despite this impressive top-line performance and the maintenance of high operating margins which suggest efficient cost management within its core business, the company's stock price has experienced a notable decline of 19%. This disconnect between operational success and share price movement suggests that investors may be pricing in future concerns or comparing ISRG against peers like Abbott who offer different capital return profiles.
A key structural characteristic mentioned is that Intuitive Surgical does not currently pay a dividend. This lack of dividend payout contrasts with some of its competitors and implies that the company retains earnings for reinvestment into growth initiatives, research and development, or share buybacks rather than returning cash directly to shareholders in the form of regular distributions.
📈 ISRG revenue surged 45% on robust surgical robotics demand.
💰 High operating margins show strong pricing power and efficiency.
📉 Stock fell 19%, creating a valuation divergence from fundamentals.
🚫 No dividend paid; earnings retained for reinvestment instead.
📈 Intuitive Surgical reported strong revenue growth of 45%, reflecting robust demand for its surgical robotics solutions.
💰 The company maintains high operating margins, indicating efficient operational execution and pricing power in its core business.
📉 Despite solid fundamentals, ISRG stock has fallen 19%, creating a divergence between operational performance and market valuation.
🚫 Intuitive Surgical does not pay a dividend, retaining earnings for reinvestment rather than shareholder cash returns.
Risk Factors
No dividend payout may deter income-focused investors.
Bullish Signals
Intuitive Surgical achieved strong revenue growth of 45%, demonstrating significant top-line expansion in its surgical robotics business.
The company maintains high operating margins, reflecting efficient cost management and strong profitability within its core operations.
Risk Factors
Intuitive Surgical does not pay a dividend, which may be viewed as a negative factor by income-focused investors compared to dividend-paying peers.
As of September 22, 2026, Intuitive Surgical (ISRG) trades at $401.65, with Wall Street analysts maintaining a consensus buy rating and a median price target of $483.00, implying approximately 20.3% upside potential. The company has demonstrated consistent revenue growth that exceeds sector averages, driven by the increasing adoption of its da Vinci surgical systems, which supports higher valuation multiples.
Despite the bullish analyst consensus, insider activity presents a notable cautionary signal, with over $127 million in stock sales recorded recently. This heavy insider selling could indicate a lack of confidence in near-term appreciation or represent strategic divestment by key personnel. Additionally, the competitive landscape is shifting as new entrants and established players develop competing robotic surgical platforms, posing potential long-term challenges to ISRG's market dominance and pricing power.
Long-term simulations suggest significant growth potential but also highlight volatility risks. CleaRank's 10-year Monte Carlo simulation projects a base case price near $631 by 2030 (a 1.6x increase from current levels), while the bear case scenario estimates a decline to around $269. Historical performance data indicates that a $10,000 investment in ISRG since September 2016 would have grown to approximately $50,332, significantly outperforming the S&P 500 benchmark which reached about $35,616 over the same period.
📈 ISRG trades at $401.65 with a median price target of $483.00.
💰 Strong revenue growth driven by da Vinci system adoption.
⚠️ Over $127 million in insider stock sales recorded recently.
🔮 Monte Carlo simulations project a base case price of $631 by 2030.
📈 ISRG trades at $401.65 with a Wall Street consensus buy rating and a median price target of $483.00.
💰 The company has consistently delivered strong revenue growth exceeding sector averages due to da Vinci system adoption.
⚠️ Over $127 million in insider stock sales have been recorded, signaling potential lack of confidence or strategic divestment.
🤖 Competing robotic surgical platforms from new and established players threaten ISRG's long-term market dominance.
📊 Historical data shows a $10,000 investment since 2016 grew to $50,332, outperforming the S&P 500 benchmark.
🔮 Monte Carlo simulations project a base case price of $631 by 2030 with a bear case downside to $269.
Bullish Signals
Revenue growth exceeds sector averages via da Vinci adoption.
Analysts rate Buy with median target of $483.00.
$10k investment since Sep 2016 worth ~$50,332.
Risk Factors
Insiders sold $127M in stock.
Competitors threaten market dominance.
Bullish Signals
ISRG has consistently delivered strong revenue growth that exceeds sector averages, driven by increasing adoption of its da Vinci surgical systems.
The majority of Wall Street analysts maintain Buy ratings with a median price target of $483.00, indicating confidence in future performance and upside potential.
Historical monthly performance trends show that a $10,000 investment in ISRG since September 2016 would be worth about $50,332 today, significantly outperforming the S&P 500.
Risk Factors
Over $127 million in stock sales by insiders has been recorded, representing heavy insider selling that could indicate a lack of confidence in near-term stock appreciation.
New entrants and established players are developing competing robotic surgical platforms, which could challenge ISRG's market dominance and pricing power over time.
Intuitive Surgical (ISRG) stock is currently trading at $393.33, presenting a technical setup where buyers could see a potential 23.9% rally to the April high of $487.45, though historical price action over the last two years suggests caution as no prior entry in this range resulted in a 20% gain before a 5% drop.
Fundamental concerns weigh on the stock, specifically a slowdown in US da Vinci procedure growth which decelerated to 12% in the second quarter of 2026 from 14% in the first. Management attributes this partly to patients delaying elective procedures due to coverage changes and the law of large numbers, while competitors' pricing strategies via extended use programs threaten to lower revenue per procedure.
Despite these headwinds, ISRG maintains strong operational momentum with hospitals continuing to purchase systems; the company placed 468 da Vinci units in Q2 2026, an 18% increase year-over-year. Revenue growth remains robust at 20.7% over the last twelve months, significantly outpacing the S&P 500 median of 8.3%, though the stock trades at a premium valuation of 44.4 times earnings compared to the index median of 22.4.
📈 ISRG faces potential 23.9% upside rally to $487.45 if clearing resistance.
⚠️ Past data shows ISRG failed to gain 20% in this range before dropping 5%.
📉 US da Vinci procedure growth slowed to 12% due to insurance coverage changes.
💰 ISRG placed 468 da Vinci systems in Q2 2026, an 18% year-over-year increase.
📊 ISRG revenue grew 20.7% over last twelve months, beating S&P 500 median.
📈 ISRG stock faces a potential 23.9% upside rally to $487.45 if it clears technical resistance at $429.72 and $452.35.
⚠️ Historical data shows that over the last two years, every time ISRG entered this price range, it failed to generate a 20% gain before dropping 5%.
📉 US da Vinci procedure growth slowed to 12% in Q2 2026 from 14% in Q1, driven by patients delaying elective care due to insurance coverage changes.
💰 ISRG placed 468 da Vinci systems in the second quarter of 2026, representing an 18% increase compared to the same period last year.
📊 Revenue grew 20.7% over the last twelve months, significantly exceeding the S&P 500 median growth rate of 8.3%.
💸 An extended use program introduced in H1 2027 allows instruments to be used more times, potentially lowering the price per procedure for benign surgeries.
📉 The stock trades at 44.4 times earnings, a premium valuation that is vulnerable if lower pricing per procedure materializes.
🔍 Management expects deferred medical conditions will eventually progress and require treatment, supporting long-term demand despite current delays.
Bullish Signals
Placed 468 da Vinci systems in Q2 2026, up 18% YoY.
Revenue grew 20.7% over last twelve months vs S&P 500 median of 8.3%.
Shift to da Vinci 5 systems accretive to revenue per procedure.
Risk Factors
US da Vinci procedure growth slowed to 12% in Q2 2026.
Insurance coverage changes affect patient care timing.
Extended use program may lower benign surgery prices.
Valuation at 44.4x earnings is double S&P 500 median.
Bullish Signals
ISRG placed 468 da Vinci systems in Q2 2026, an 18% year-over-year increase in hospital placements.
Revenue grew 20.7% over the last twelve months, significantly outpacing the S&P 500 median of 8.3%.
The shift toward da Vinci 5 systems has been accretive to revenue per procedure.
Risk Factors
US da Vinci procedure growth slowed to 12% in Q2 2026 from 14% in Q1, indicating a slowdown in elective procedures.
Customers report that insurance coverage changes are affecting when patients seek care for treatable conditions.
An extended use program starting in H1 2027 may lower the price per procedure for benign surgeries, potentially denting margins.
The stock trades at 44.4 times earnings, a valuation more than double the S&P 500 median of 22.4x, making it sensitive to growth disappointments.
Intuitive Surgical (ISRG) shares rose approximately 1% in after-hours trading following the release of quarterly financial results that exceeded market expectations. The medical robotics provider reported an adjusted earnings per share of $1.50, surpassing analyst estimates of $1.41, while revenue reached $1.89 billion, slightly beating the consensus forecast.
The company's positive performance was driven by stronger-than-anticipated operational metrics across its robotic-assisted surgical solutions portfolio. This beat in both top-line revenue and bottom-line earnings suggests robust demand for its core products despite broader market volatility observed in other sectors during the extended trading session.
📈 ISRG shares gained 1% after-hours following earnings beat.
💰 Adjusted EPS of $1.50 exceeded analyst estimates of $1.41.
Intuitive Surgical (ISRG) shares edged higher on September 17, 2026, closing at USD 383.54 on the Nasdaq following a significant regulatory milestone and strong quarterly performance. The company received CE mark approval in Europe for its da Vinci SP single-port robotic system to perform transvaginal gynecologic procedures, expanding its approved indications and deepening its presence in minimally invasive women's health markets.
Fundamental growth remains robust despite a broader stock correction of 32.3% year-to-date in 2026. The second quarter of 2026 delivered year-on-year increases in both revenue and da Vinci procedure volume, validating the company's expansion strategy. Additionally, Intuitive Surgical highlighted continued growth in installed systems and recurring revenue from instruments and accessories, reinforcing the durability of its razor-and-blades business model.
Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average price target of USD 508.68, implying approximately 32.6% upside from current levels. While Vice President Fredrik Widman executed a planned Rule 10b5-1 sale of shares worth roughly USD 407,765, institutional investors maintain a dominant 83.6% ownership stake, signaling strong professional confidence in the company's long-term trajectory and valuation entry point.
📈 ISRG stock closed at USD 383.54 on Sept 17, 2026, gaining 0.33% on EU approval for da Vinci SP.
✅ CE mark now covers transvaginal gynecologic procedures, expanding da Vinci SP indications in Europe.
📊 Q2 2026 revenue and procedure volume grew year-over-year, strengthening the razor-and-blades ecosystem.
📉 Shares declined 32.3% YTD from USD 566.36 high despite operational growth momentum.
📈 Intuitive Surgical stock closed at USD 383.54 on September 17, 2026, gaining 0.33% as investors reacted to new EU approval for the da Vinci SP system.
✅ The European CE mark now covers transvaginal gynecologic procedures for the da Vinci SP, expanding the platform's approved indications in the region.
📊 Q2 2026 fundamentals showed year-on-year growth in revenue and da Vinci procedure volume, underscoring continued business expansion.
💰 Recurring revenue from instruments and accessories grew in Q2 2026, strengthening the company's razor-and-blades ecosystem model.
🎯 Analysts maintain a Moderate Buy rating with an average price target of USD 508.68, suggesting roughly 32.6% upside potential.
📉 Shares have declined 32.3% year-to-date in 2026 from a high of USD 566.36, creating a valuation contrast with operational growth.
👔 Vice President Fredrik Widman sold 1,089 shares under a Rule 10b5-1 plan for approximately USD 407,765 on September 17.
🏦 Institutional investors hold roughly 83.6% of Intuitive Surgical's outstanding shares, indicating strong professional ownership.
🔬 The company continues to expand its installed base of da Vinci systems while maintaining momentum in robotic procedures.
Bullish Signals
da Vinci SP got CE mark for transvaginal procedures in Europe.
Risk Factors
Shares fell 32.3% YTD in 2026 below analyst valuations.
VP sold 1,089 shares worth USD 407,765 on Sept 17, 2026.
Bullish Signals
Intuitive Surgical received CE mark approval in Europe for the da Vinci SP system to perform transvaginal gynecologic procedures, expanding its market presence.
Q2 2026 revenue and da Vinci procedure volume both increased year-on-year, demonstrating sustained business momentum despite stock price corrections.
The company reported continued growth in installed da Vinci systems and recurring revenue from instruments and accessories in Q2 2026.
Analyst consensus rates the stock as a Moderate Buy with an average price target of USD 508.68, implying approximately 32.6% upside from current levels.
Institutional investors maintain a dominant 83.6% ownership stake in Intuitive Surgical shares, reflecting strong professional confidence.
Risk Factors
Intuitive Surgical shares have fallen by 32.3% year-to-date in 2026 from a starting level of USD 566.36, trading below typical analyst valuation benchmarks.
Vice President Fredrik Widman sold 1,089 shares worth approximately USD 407,765 under a Rule 10b5-1 plan on September 17, 2026.
Intuitive Surgical (ISRG) is being re-evaluated as a compelling long-term investment, though the analyst notes that current valuation levels require strong execution to justify the price. The company's Q2 financial performance showed revenue growth moderating to 18.5%, while operating income surged by 30.7% and margins expanded even after adjusting for tariff refunds.
The business model is driven significantly by recurring revenue from instruments, services, and leases, which accounted for 86% of incremental sales. This recurring nature is supported by strong system adoption and installed base growth, which in turn support future procedure volumes. The analyst concludes that while lower multiples offer a better risk-return balance, the stock has been upgraded to a Hold rating.
The upgrade reflects a shift from a previous bullish stance taken in June, where the analyst liked the company's hospital relationships and surgical platform but was concerned about the price. The current view suggests that while procedure growth and demand require close monitoring, the resilient earnings and lower multiples present an improved opportunity compared to the higher valuation previously observed.
📈 ISRG upgraded to Hold as lower multiples improve risk-return balance.
💰 Q2 revenue grew 18.5% while operating income surged 30.7%.
🔄 Recurring revenue from instruments and services drove 86% of sales.
🏥 Strong installed base growth supports future procedure volumes and demand.
⚖️ Current valuation requires strong execution to justify the price.
📈 Intuitive Surgical (ISRG) is upgraded to a Hold rating as the sell case loses ground due to lower multiples and resilient earnings offering better risk-return balance.
💰 Q2 revenue growth moderated to 18.5%, while operating income surged 30.7% with expanded margins even after adjusting for tariff refunds.
🔄 Recurring revenue from instruments, services, and leases drove 86% of incremental sales, highlighting the strength of the installed base.
🏥 Strong system adoption and installed base growth continue to support future procedure volumes and long-term demand.
⚖️ The analyst previously held a bullish view in June but now emphasizes that current valuation demands strong execution to justify the price.
Bullish Signals
Operating income surged 30.7% in Q2.
Margins expanded despite tariff refunds.
Recurring revenue drove 86% of sales.
Installed base growth supports future demand.
Risk Factors
Revenue growth slowed to 18.5%.
Valuation remains high despite execution risks.
Bullish Signals
Operating income surged 30.7% in Q2, demonstrating resilient earnings despite moderate revenue growth.
Margins expanded during the quarter even after adjusting for tariff refunds, indicating operational efficiency.
Recurring revenue from instruments, services, and leases drove 86% of incremental sales, providing stable cash flow.
System adoption and installed base growth are supporting future procedure volumes, ensuring long-term demand.
Risk Factors
Revenue growth moderated to 18.5%, indicating a slowdown in top-line expansion compared to previous periods.
Current valuation levels are considered high, requiring strong execution to justify the price for investors.
Intuitive Surgical (NASDAQ:ISRG) EVP Mark Brosius sold 46 shares of the company's stock on September 8th under a pre-arranged Rule 10b5-1 trading plan. The transaction, valued at $16,616.58, reduced his personal holding by 5.22%, leaving him with 835 shares worth approximately $301,627. This insider sale is a routine disclosure event and does not necessarily indicate a change in the company's long-term outlook.
The medical technology firm recently reported strong quarterly financial results released on July 16th. Intuitive Surgical generated revenue of $2.89 billion, surpassing analyst consensus estimates of $2.83 billion, while posting earnings per share (EPS) of $2.80 against an expected $2.48. The company's revenue grew by 18.4% year-over-year, driven by its da Vinci Surgical System used across various surgical specialties.
Analyst sentiment remains mixed but generally positive regarding the stock's valuation and growth trajectory. While Royal Bank of Canada lowered its price target to $600 and Bank of America reduced theirs to $515, major institutions like KeyCorp and Piper Sandler maintain 'overweight' or 'outperform' ratings. Institutional ownership stands at 83.64%, with several hedge funds increasing their stakes in the fourth quarter.
📉 EVP Mark Brosius sold 46 shares under Rule 10b5-1 plan.
💰 Q2 revenue hit $2.89B, beating estimates by $0.06B.
📈 EPS reached $2.80, significantly exceeding analyst expectations of $2.48.
🚀 Revenue grew 18.4% YoY driven by da Vinci system demand.
📊 Stock trades at 40.46 P/E with $508.68 average price target.
📉 EVP Mark Brosius sold 46 shares of ISRG for $16,616.58 on September 8th under a pre-arranged Rule 10b5-1 trading plan.
💰 The company reported Q2 revenue of $2.89 billion, beating the consensus estimate of $2.83 billion by $0.06 billion.
📈 Intuitive Surgical posted EPS of $2.80 for the quarter, significantly exceeding analyst expectations of $2.48.
🚀 Revenue grew 18.4% year-over-year, demonstrating continued strong demand for the da Vinci Surgical System.
🏦 The stock trades at a P/E ratio of 40.46 with a market capitalization of $124.79 billion.
📊 Analyst consensus rating is 'Moderate Buy' with an average price target of $508.68.
Bullish Signals
Revenue beat estimates at $2.89 billion.
EPS of $2.80 exceeded consensus of $2.48.
Revenue grew 18.4% year-over-year.
Analysts maintain 'overweight' ratings on stock.
Hedge funds increased stakes significantly.
Risk Factors
RBC cut price target from $650 to $600 due to conservative valuation.
BofA lowered price target from $520 to $515 adjusting near-term expectations.
Bullish Signals
Intuitive Surgical beat quarterly revenue estimates by $0.06 billion, reporting $2.89 billion in revenue.
The company significantly exceeded earnings expectations with EPS of $2.80 versus the consensus of $2.48.
Revenue grew 18.4% year-over-year, indicating robust market expansion for its robotic surgical systems.
KeyCorp and Piper Sandler maintain 'overweight' ratings on the stock, signaling confidence in its long-term prospects.
High Note Wealth LLC increased its position by 50%, while other hedge funds like Prosperity Consulting Group boosted stakes.
Risk Factors
Royal Bank of Canada lowered its price target from $650 to $600, citing a more conservative valuation outlook.
Bank of America decreased its price target from $520 to $515, reflecting a slight adjustment in near-term expectations.
Intuitive Surgical (ISRG) is trading at a forward 12-month P/E of 30.26X, significantly below its 10-year median of 58.18X and historical high of 93.22X, marking its cheapest valuation in a decade following a price decline exceeding 40%. Despite the steep multiple compression, the company maintains a 'D' Value Score, indicating it is not yet considered an outright bargain relative to the broader medical instruments industry average of 25.96X.
Fundamental performance remains robust with second-quarter 2026 revenue rising 19% year-over-year to $2.89 billion and adjusted EPS advancing 28%. Total procedures increased 16%, driven by a 15% rise in da Vinci systems and a 36% surge in Ion procedures. Recurring revenue climbed to $2.47 billion, representing 85% of total revenue, while system utilization improved across both platforms.
Management maintains its 2026 guidance for da Vinci procedure growth between 13.5% and 15.5%, citing international expansion as a key driver with 20% growth in Europe and Asia. However, the outlook incorporates near-term uncertainties including potential impacts from U.S. patient behavior changes, competitive pressures in China, European capital constraints, and the broader effects of obesity drug adoption on surgical volumes.
While ISRG faces headwinds such as higher freight costs, semiconductor expenses, and elevated depreciation during platform transitions, its strong product pipeline offers a counterweight to concerns. The company has installed over 1,700 da Vinci 5 systems and is rapidly gaining traction with single-port procedures, which grew 61% in the quarter. Analysts suggest holding for existing investors while prospective buyers may wait for further evidence of accelerating growth before committing aggressively.
📉 Stock down 40% from peak, trading at 30.26X forward P/E.
💰 Q2 revenue up 19% to $2.89B with EPS rising 28%.
🔧 Procedures rose 16%; Ion procedures jumped 36% to 48,000.
⚠️ U.S. growth faces headwinds from ACA subsidies and obesity drugs.
🇨🇳 China expansion challenged by competition and tender volume issues.
📉 ISRG stock has declined over 40% from its January peak, trading at a forward P/E of 30.26X versus a 10-year median of 58.18X.
💰 Second-quarter 2026 revenue increased 19% year-over-year to $2.89 billion with adjusted EPS advancing 28%.
🔧 Total procedures rose 16%, with da Vinci procedures up 15% and Ion procedures jumping 36% to 48,000.
📈 Recurring revenue climbed 19% to $2.47 billion, now representing 85% of total revenue base.
🌍 International da Vinci procedures grew 20% in the quarter, with Europe and Asia each advancing 20%.
⚠️ Management forecasts U.S. procedure growth moderation due to ACA subsidy changes and obesity drug impacts.
🇨🇳 China faces competitive pressure and tender volume challenges affecting near-term international expansion.
💸 Gross margin outlook raised to 68-69% but elevated spending on freight, semiconductors, and depreciation expected.
🤖 Over 1,700 da Vinci 5 systems are installed with more than 100 planned updates rolling out globally.
📊 Single-port procedures increased 61% as the global installed base reached 445 systems.
🏥 ISRG lags the broader medical sector and its own industry peers over the past three months.
🔬 The company is progressing with ROSE and EBUS programs and submitted a next-gen flexible endoscope for FDA clearance.
Bullish Signals
Trades at forward P/E of 30.26X vs 10-year median of 58.18X.
Q2 2026 revenue rose 19% YoY to $2.89B with EPS up 28%.
Ion procedures jumped 36% in the quarter, surpassing 400,000 cumulatively.
International da Vinci procedures grew 20%, with Europe and Asia each advancing 20%.
Recurring revenue climbed 19% to $2.47B, representing a resilient 85% of total.
Risk Factors
China competition moderates U.S. procedure trends affecting growth.
Higher freight and chip costs pressure profitability margins.
Intuitive Surgical (ISRG) shares closed on September 4, 2026, at USD 366.70 on the Nasdaq, marking a 2.9% decline from the prior session. The stock finished significantly below its recent peak, trading approximately 39% under its 52-week high of roughly USD 603.88 and down about 21.5% over the past twelve months.
Despite the recent price weakness, market data indicates that Intuitive Surgical trades at a discount relative to analyst consensus, with an average price target near USD 508.68. The company maintains a substantial market capitalization of approximately USD 131.38 billion, reflecting its status as a major player in the medical technology sector.
Trading volume for the session remained consistent with recent patterns, though Intuitive Surgical underperformed the broader Nasdaq Composite index and the wider healthcare cohort. With no company-specific earnings reports or scheduled events imminent, near-term stock movements are expected to be driven primarily by broader market dynamics, sector performance, and macroeconomic indicators rather than specific corporate developments.
📉 ISRG stock closed down 2.9% at USD 366.70 on September 4, 2026.
📊 Shares trade 39% below the 52-week high of USD 603.88.
📉 The stock has declined roughly 21.5% over the past twelve months.
💰 ISRG maintains a market capitalization of around USD 131.38 billion.
🎯 Analyst consensus suggests an average price target near USD 508.68.
📉 Intuitive Surgical stock closed down 2.9% at USD 366.70 on September 4, 2026.
📊 Shares are trading approximately 39% below their 52-week high of USD 603.88.
📉 The stock has declined roughly 21.5% over the past twelve months.
💰 Intuitive Surgical maintains a market capitalization of around USD 131.38 billion.
🎯 Analyst consensus suggests an average price target near USD 508.68, indicating the current price is below expectations.
📉 The company underperformed the broader Nasdaq Composite and healthcare indices during the session.
📅 No earnings reports or major corporate events are scheduled for the immediate future.
Bullish Signals
Intuitive Surgical trades at a discount relative to analyst consensus, with an average price target near USD 508.68 suggesting potential upside from current levels.
The company maintains a robust market capitalization of approximately USD 131.38 billion, indicating strong overall market valuation despite recent short-term declines.
Risk Factors
Intuitive Surgical shares closed down 2.9% and are trading roughly 39% below their 52-week high.
The stock has experienced a significant drawdown of approximately 21.5% over the past twelve months.
Intuitive Surgical underperformed the broader Nasdaq Composite index and the wider healthcare sector during the trading session.
Intuitive Surgical (ISRG), a pioneer in surgical robotics, is experiencing a significant growth slowdown following post-pandemic highs. The company's market share faces increasing pressure as medical device giants like Medtronic and Johnson & Johnson enter the competitive landscape with their own robotic systems, creating material competition for Intuitive's core da Vinci platform.
Despite the competitive headwinds, Intuitive Surgical maintains a robust financial foundation driven by its service business. Approximately 75% of the company's top line now comes from maintenance and servicing contracts for existing da Vinci systems, providing a steady annuity-like revenue stream that persists as long as these surgical robots remain in clinical use.
Management views future growth through continued technological advancements, specifically focusing on integrating artificial intelligence into robotic surgery applications. Historically, the company has demonstrated resilience by recovering from previous drawdowns to achieve higher highs, leading analysts to characterize the current stock sell-off as a potential buying opportunity for investors.
📉 Growth slowed due to increased competition in surgical robotics.
🏥 Medtronic and Johnson & Johnson now challenge market dominance.
💰 75% revenue comes from da Vinci system maintenance contracts.
🔄 Service model provides steady annuity-like income stream.
🤖 AI advances drive future growth opportunities for robotic surgery.
📉 Intuitive Surgical's growth has slowed significantly since post-pandemic peaks due to increased competition in the surgical robotics market.
🏥 Major medical device competitors including Medtronic and Johnson & Johnson are now entering the fray, challenging Intuitive Surgical's dominance.
💰 Approximately 75% of Intuitive Surgical's revenue is derived from maintenance and servicing contracts for existing da Vinci systems.
🔄 This service-based business model provides a steady annuity-like income stream that continues as long as da Vinci systems are in use.
🤖 The company is pursuing growth opportunities through technological advances, particularly in the application of artificial intelligence to robotic surgery.
📈 Historical performance suggests Intuitive Surgical has recovered from previous drawdowns to reach higher highs, indicating resilience.
Bullish Signals
Intuitive Surgical generates a steady annuity-like revenue stream where approximately 75% of its top line comes from maintenance and servicing of existing da Vinci systems.
The company has a historical track record of recovering from previous drawdowns and achieving higher highs, suggesting resilience in the face of market volatility.
Risk Factors
Intuitive Surgical's growth has slowed significantly since post-pandemic highs due to material competition entering the surgical robotics market.
The competitive landscape is intensifying as medical device giants like Medtronic and Johnson & Johnson launch their own robotic systems, challenging Intuitive Surgical's market position.
Intuitive Surgical (ISRG) remains the undisputed leader in robotic-assisted surgery, trading at a premium valuation of 42.5 times earnings compared to peers like Medtronic at 24.2x. Despite commanding the highest operating margin in its peer group at 31% and delivering robust revenue growth of 21% over the last twelve months, the stock has underperformed significantly with a -21% return over the past year, trailing the S&P 500's gains.
The company's high valuation is driven by a strong upgrade cycle for its da Vinci 5 system, evidenced by placing 468 systems in the second quarter, with nearly half being the newer model. International expansion continues to provide crucial growth support, with procedure volume increasing 20% outside the U.S., offsetting signs of maturation in the domestic market where patient insurance changes are affecting deferrable procedures.
Investors are closely watching whether ISRG can meet its full-year guidance for worldwide da Vinci procedure growth between 13.5% and 15.5%. Management has affirmed this target, suggesting that if achieved, it would validate the bull case that the U.S. slowdown is manageable. The core metric driving recurring revenue remains the number of procedures performed, making adherence to these targets critical for sustaining its premium market capitalization.
📈 ISRG trades at 42.5x earnings vs Medtronic's 24.2x despite underperformance.
💰 Achieved 31% operating margin, outperforming industry and rival Medtronic.
🚀 Revenue grew 21% with 468 da Vinci systems placed in Q2.
⚠️ U.S. procedure growth moderated due to patient insurance coverage changes.
🌍 International procedure volume expanded 20% outside the U.S.
📈 ISRG trades at a premium 42.5x earnings multiple compared to peer Medtronic's 24.2x despite recent stock underperformance.
💰 The company achieved a leading 31% operating margin, significantly outperforming the industry average and rival Medtronic's 18.8%.
🚀 Revenue grew 21% over the last twelve months, demonstrating superior execution against diversified competitors like Medtronic.
🔧 A healthy upgrade cycle is underway with 468 da Vinci systems placed in Q2, including 246 units of the new da Vinci 5 model.
🌍 International growth remains robust with procedure volume expanding 20% outside the U.S. to offset domestic market saturation.
⚠️ U.S. procedure growth has moderated due to changes in patient insurance coverage affecting deferrable surgical procedures.
🎯 Management reaffirmed a full-year guidance range for worldwide da Vinci procedure growth between 13.5% and 15.5%.
📉 The stock delivered a -21% return over the last twelve months, badly trailing the S&P 500's +19.2% gain.
Bullish Signals
ISRG commands the highest operating margin in its peer group at 31%, significantly outperforming rivals like Medtronic.
Revenue grew 21% over the last twelve months, demonstrating superior operational execution compared to diversified competitors.
The company is executing a powerful upgrade cycle with strong capital equipment sales, placing 468 da Vinci systems in Q2 alone.
International expansion provides a crucial growth offset with procedure volume growing 20% outside the U.S. market.
Risk Factors
The stock has delivered a -21% return over the last twelve months, significantly underperforming the S&P 500's +19.2% gain.
Growth in the U.S. market is moderating due to changes in patient insurance coverage affecting deferrable procedures.
Intuitive Surgical (ISRG) EVP Mark Brosius sold 77 shares of the company's stock on August 17th for a total value of $30,081.59 at an average price of $390.67 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and resulted in a 6.08% decrease in his direct ownership, leaving him with 1,189 shares valued at approximately $464,506. This insider sale is a routine disclosure filed with the SEC.
The company recently reported strong quarterly financial performance, beating analyst expectations for both earnings per share and revenue. Intuitive Surgical posted EPS of $2.80 compared to a consensus of $2.48, while revenue reached $2.89 billion against expectations of $2.83 billion. Year-over-year revenue growth was 18.4%, driven by the company's core robotic-assisted surgical systems and related technologies.
Institutional investors have significantly increased their stakes in Intuitive Surgical over the past few quarters, with major entities like Norges Bank, Bank of New York Mellon, and J. Stern & Co. adding substantial positions. Hedge funds and wealth management firms collectively hold a large portion of the float, indicating strong institutional confidence despite mixed analyst price targets ranging from $500 to $590.
📉 ISRG EVP Mark Brosius sold 77 shares for $30,081.59 under Rule 10b5-1 plan.
💰 Q2 EPS hit $2.80, beating consensus by $0.32.
📈 Revenue reached $2.89 billion, up 18.4% year-over-year.
🏦 Norges Bank acquired new stake worth $2.86 billion in Q4.
📊 Institutional ownership stands at 83.64% with recent additions.
📉 ISRG EVP Mark Brosius sold 77 shares for $30,081.59 under a pre-arranged Rule 10b5-1 trading plan on August 17th.
💰 The company reported Q2 EPS of $2.80, beating the consensus estimate of $2.48 by $0.32.
📈 ISRG revenue reached $2.89 billion for the quarter, exceeding analyst expectations of $2.83 billion.
🚀 Revenue grew 18.4% year-over-year, demonstrating continued strong demand for robotic surgical systems.
🏦 Norges Bank acquired a new stake worth approximately $2.86 billion in the fourth quarter.
📊 Institutional ownership stands at 83.64%, with significant additions from J. Stern & Co. and Northwestern Mutual.
🎯 Analyst consensus rating is 'Moderate Buy' with a target price of $508.68 according to MarketBeat.
📉 Bank of America lowered its price target from $520 to $515 in a recent research report.
📈 Sanford C. Bernstein reaffirmed an 'outperform' rating on ISRG shares in August.
💻 The company maintains a market cap of $140.51 billion with a PE ratio of 45.56.
Bullish Signals
EPS beat at $2.80 vs $2.48 consensus.
Revenue hit $2.89B, beating $2.83B estimates.
Revenue grew 18.4% year-over-year in robotics.
Norges Bank added $2.86B stake in Q4.
Oppenheimer upgraded to 'outperform' with $500 target.
Risk Factors
Bank of America cut price target from $520 to $515.
Mizuho assigned neutral rating with $500 price target.
Citigroup lowered price target from $590 to $500.
High PE ratio of 45.56 limits upside if growth slows.
Bullish Signals
Intuitive Surgical beat Q2 earnings estimates with EPS of $2.80 versus the consensus of $2.48.
The company reported revenue of $2.89 billion, surpassing analyst expectations of $2.83 billion.
Revenue increased 18.4% year-over-year, highlighting strong growth in its robotic surgical systems business.
Norges Bank added a new stake worth $2.86 billion to its holdings in the fourth quarter.
J. Stern & Co. LLP grew its stake by 18,504.6% in the fourth quarter, adding over 2 million shares.
Arrowstreet Capital Limited Partnership lifted its stake by 95.3% in the first quarter.
Sanford C. Bernstein reaffirmed an 'outperform' rating on ISRG shares in a recent research note.
Oppenheimer upgraded its rating to 'outperform' and set a $500 price objective for the stock.
Risk Factors
Bank of America dropped its price target from $520.00 to $515.00 in a research report.
Mizuho assigned a 'neutral' rating and set a $500.00 price target on ISRG shares.
Citigroup reduced its price target from $590.00 to $500.00, though it maintained a 'buy' rating.
The stock trades at a high PE ratio of 45.56, which may limit upside potential if growth slows.
Intuitive Surgical (ISRG) is a leader in robotic-assisted surgery with a market capitalization of $125.08 billion as of July 20, 2026. Despite releasing solid quarterly results where revenue and Da Vinci procedure growth topped consensus estimates, the stock faced headwinds from disappointing system placements in China and Japan. The company recently repurchased 2.3 million shares for $1.1 billion in the first quarter of 2026, signaling management's confidence in its long-term value despite near-term volatility.
TCW Concentrated Large Cap Growth Fund maintains a constructive stance on ISRG, highlighting the company's 20-year lead over competitors and its strong competitive moat in minimally invasive care. The fund notes that while shares have been challenged year-to-date due to negative sentiment in healthcare medtech stocks and high valuation multiples, management has raised 2026 guidance. The firm remains optimistic about the upcoming launch of the Da Vinci 5 system, which is expected to drive further penetration into new hospitals and procedure categories.
Although TCW acknowledges ISRG's potential, it currently views AI-focused stocks as offering greater promise for higher returns within a shorter timeframe compared to Intuitive Surgical. Hedge fund holdings in the company decreased slightly from 109 portfolios in the previous quarter to 103 at the end of the first quarter. The article concludes that while ISRG is not on TCW's list of most popular stocks heading into 2026, the investment firm remains constructive on its long-term prospects.
📈 ISRG revenue and Da Vinci procedure growth beat consensus estimates.
📉 Shares fell on healthcare medtech sentiment despite strong fundamentals.
🌏 System placements disappointed specifically in China and Japan markets.
💰 ISRG repurchased 2.3 million shares worth $1.1 billion in Q1 2026.
🚀 Management raised 2026 guidance citing confidence in future growth.
📈 Intuitive Surgical (ISRG) reported solid quarterly results with revenue and Da Vinci procedure growth exceeding consensus estimates.
📉 Shares of ISRG moved lower despite strong fundamentals due to negative investor sentiment in healthcare medtech and high valuation multiples.
🌏 System placements for ISRG continue to disappoint specifically in the China and Japan markets.
💰 ISRG repurchased 2.3 million shares worth $1.1 billion during the first quarter of 2026.
Johnson & Johnson (JNJ) has received FDA De Novo authorization for its OTTAVA robotic surgical system, officially entering the U.S. soft-tissue market where Intuitive Surgical (ISRG) currently dominates. The OTTAVA platform features a unique table-integrated architecture that occupies 30% to 50% less space than traditional boom-mounted systems, potentially appealing to hospitals with limited operating room capacity. This strategic move aims to convert J&J's existing surgical portfolio and relationships into meaningful market share against the established leader.
Intuitive Surgical maintains a formidable competitive position with an installed base of 11,710 da Vinci systems as of Q2 2026, up 12% year-over-year. The company reported strong financial performance in fiscal Q2, with revenue rising 19% to $2.89 billion and instruments/accessories revenue increasing 18% to $1.73 billion. Despite the new entrant, Intuitive's procedure volume grew approximately 16%, indicating that hospitals continue adopting newer platforms like the da Vinci 5 even as competition intensifies.
J&J plans a selective commercial launch in the U.S. with select customers to focus on early success and gather real-world feedback before broader expansion. While the OTTAVA system is unlikely to materially impact J&J's near-term financial results given the limited rollout, successful adoption could eventually strengthen its MedTech business, which generated $8.93 billion in Q2 2026 sales. Investors will closely monitor the pace of placements and indication expansion, particularly in urology, to determine if OTTAVA can truly challenge Intuitive's leadership.
Analysts suggest that while OTTAVA represents a credible platform with differentiated design, Intuitive Surgical remains difficult to displace due to its entrenched ecosystem of recurring revenue from instruments and services. The article concludes that the FDA authorization marks the beginning of a commercial challenge rather than an immediate threat to Intuitive's market dominance, though J&J's broader portfolio offers potential synergies for future growth.
📋 FDA authorizes J&J OTTAVA robotic system for U.S. soft-tissue market.
🔧 OTTAVA table-integrated design saves 30% to 50% space vs boom systems.
🏥 System approved for gastric bypass, gastrectomy, and cholecystectomy procedures.
🚀 J&J launches OTTAVA selectively with select U.S. customers for training.
⚖️ Analysts see urology authorization as key to competing with Intuitive Surgical.
📋 Johnson & Johnson received FDA De Novo authorization for its OTTAVA robotic surgical system, entering the U.S. soft-tissue market.
🔧 OTTAVA features a table-integrated design occupying 30% to 50% less space than traditional boom-mounted systems.
🏥 The system is authorized for multiple upper-abdominal procedures including gastric bypass, gastrectomy, and cholecystectomy.
🚀 J&J will launch OTTAVA selectively with select U.S. customers to focus on early customer success and training.
📊 Intuitive Surgical reported 11,710 installed da Vinci systems at the end of Q2 2026, up 12% from the previous year.
💰 Intuitive Surgical revenue rose 19% to $2.89 billion in fiscal Q2, with instruments/accessories revenue up 18% to $1.73 billion.
📈 Worldwide da Vinci and Ion procedure volume grew approximately 16% for Intuitive Surgical in the second quarter.
🔬 J&J is conducting an ongoing U.S. clinical trial for OTTAVA in inguinal hernia procedures.
⚖️ Analysts view urology authorization as a key differentiator necessary for more direct competition with Intuitive Surgical.
🛡️ Intuitive Surgical's recurring revenue model from instruments and services creates a strong barrier to entry for new competitors.
Bullish Signals
FDA authorized OTTAVA for multiple upper-abdominal procedures.
OTTAVA occupies 30% to 50% less space than traditional systems.
Revenue rose 19% to $2.89 billion in fiscal Q2 2026.
468 da Vinci systems placed, including 246 da Vinci 5 units.
MedTech segment generated $8.93 billion in second-quarter 2026 sales.
Risk Factors
OTTAVA unlikely to affect J&J near-term results due to limited launch.
Intuitive Surgical has 11,710 da Vinci systems generating recurring revenue.
Hospital adoption of OTTAVA remains unproven requiring extensive training.
Competition has not yet disrupted Intuitive Surgical's growth trajectory.
Urology authorization necessary for OTTAVA to challenge Intuitive Surgical.
Bullish Signals
Johnson & Johnson has secured FDA De Novo authorization for the OTTAVA robotic surgical system, validating its technology for multiple upper-abdominal procedures.
OTTAVA's table-integrated architecture offers a unique value proposition by occupying 30% to 50% less space than traditional systems, appealing to hospitals with capacity constraints.
Intuitive Surgical demonstrated robust growth with revenue rising 19% to $2.89 billion and procedure volume increasing 16% in fiscal Q2 2026.
Intuitive Surgical placed 468 da Vinci systems in the quarter, including 246 units of the newer da Vinci 5 platform, showing strong market adoption.
J&J's MedTech segment generated $8.93 billion in second-quarter 2026 sales, providing a solid financial foundation for future robotic surgery investments.
Intuitive Surgical's instruments and accessories revenue increased 18% to $1.73 billion, highlighting the strength of its recurring revenue ecosystem.
Risk Factors
OTTAVA is unlikely to materially affect Johnson & Johnson's near-term financial results due to a limited selective launch strategy.
Intuitive Surgical holds a significant competitive advantage with an installed base of 11,710 da Vinci systems that generate recurring revenue from instruments and services.
Hospital adoption of OTTAVA remains unproven as the system requires extensive training, workflow integration, and sufficient procedure volumes to justify investment.
Competition has not yet disrupted Intuitive Surgical's growth trajectory, suggesting its ecosystem remains resilient despite new entrants like J&J.
Urology authorization is viewed by analysts as a necessary condition for OTTAVA to mount a more direct challenge to Intuitive Surgical's dominance.
Intuitive Surgical Director Amy Ladd sold 72 shares of the company's stock on August 11th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $393.10 per share, totaling approximately $28,303, leaving her with 179 shares valued at roughly $70,365. This sale represents a 28.69% decrease in her personal ownership stake.
The medical technology company recently reported strong quarterly financial results released on July 16th. Intuitive Surgical achieved revenue of $2.89 billion, surpassing analyst expectations of $2.83 billion, and posted earnings per share of $2.80 against a consensus estimate of $2.48. Revenue grew by 18.4% year-over-year, while the company maintained a net margin of 28.45% and a return on equity of 16.91%.
Institutional investor activity shows mixed signals alongside recent analyst adjustments. Several hedge funds, including Brighton Jones LLC and Main Street Financial Solutions LLC, significantly increased their stakes in the second quarter. However, major analysts like Stifel Nicolaus and BTIG Research lowered their price targets to $550 and $469 respectively, though the consensus rating remains a 'Moderate Buy' with a target price of $509.02.
💰 Q2 revenue hit $2.89B, beating estimates by $60M.
📈 EPS reached $2.80, topping the consensus of $2.48.
🏦 Institutional ownership stands at 83.64% with increased holdings.
📉 Stifel lowered price target to $550 while keeping 'buy'.
🔭 Full-year EPS forecast is $8.87 for current fiscal year.
📉 Director Amy Ladd sold 72 shares for $28,303 under a pre-arranged Rule 10b5-1 trading plan on August 11th.
💰 The company reported Q2 revenue of $2.89 billion, beating estimates by $60 million and growing 18.4% year-over-year.
📈 Intuitive Surgical posted earnings per share of $2.80, significantly topping the consensus estimate of $2.48.
🏦 Institutional ownership remains high at 83.64%, with Brighton Jones LLC increasing holdings by 24.9% in Q4.
📉 Analyst Stifel Nicolaus lowered its price target from $670 to $550 while maintaining a 'buy' rating.
📉 BTIG Research reduced its price objective from $512 to $469, citing a 'buy' recommendation.
📊 The stock trades at a P/E ratio of 45.96 with a market capitalization of $141.75 billion.
🔭 Analysts forecast full-year earnings per share of $8.87 for the current fiscal year.
🏥 Intuitive Surgical's core business focuses on da Vinci robotic-assisted surgical systems and related instruments.
📈 Royal Bank Of Canada reduced its price target to $600 but maintained an 'outperform' rating.
Director Amy Ladd sold holdings (28.69% decrease).
Stifel lowered price target from $670 to $550.
BTIG reduced objective from $512 to $469.
Royal Bank of Canada cut target from $650 to $600.
Bullish Signals
Revenue of $2.89 billion exceeded analyst expectations of $2.83 billion, demonstrating strong market demand.
Earnings per share of $2.80 beat the consensus estimate of $2.48 by $0.32, indicating operational efficiency.
Year-over-year revenue growth of 18.4% highlights sustained business expansion in the medical robotics sector.
Net margin of 28.45% and return on equity of 16.91% reflect robust profitability and capital allocation.
Multiple institutional investors, including Brighton Jones LLC and Main Street Financial Solutions LLC, increased their stakes significantly in recent quarters.
Risk Factors
Director Amy Ladd sold a substantial portion of her holdings (28.69% decrease), which can sometimes signal reduced confidence or liquidity needs.
Analyst Stifel Nicolaus lowered its price target from $670 to $550, suggesting potential valuation concerns despite the buy rating.
BTIG Research reduced its price objective from $512 to $469, indicating a more conservative near-term outlook.
Royal Bank Of Canada cut its price target from $650 to $600, reflecting some caution among major financial institutions.
Intuitive Surgical (ISRG) saw significant institutional activity in recent quarters, highlighted by BSN Capital Partners reducing its stake by 41.5% to 100,000 shares worth $49.6 million. Conversely, major funds like Norges Bank, J. Stern & Co., and Northwestern Mutual Wealth Management aggressively increased their holdings, with J. Stern raising its position by over 18,500% to own more than $1.2 billion in stock.
Analyst sentiment remains mixed regarding the company's valuation. While Barclays maintains an overweight rating with a $651 price target, Deutsche Bank and HSBC have downgraded their ratings or lowered targets to the low $300s. The consensus among twenty analysts is currently a Moderate Buy with an average price target of $509.02.
Insider trading data shows recent sales by executives Iman Jeddi and Gary Loeb, who sold shares under pre-arranged Rule 10b5-1 plans. Over the last ninety days, insiders have collectively sold approximately $2.8 million in stock, though they still retain a small 0.60% ownership stake in the company.
📉 BSN Capital reduced ISRG holdings by 41.5% to 100k shares.
🚀 J. Stern & Co. surged stake 18,504.6% to $1.2 billion value.
📈 Norges Bank added massive $2.86 billion position in Q4.
📉 Deutsche Bank downgraded stock with new $366 price target.
💼 Insiders sold 6,634 shares worth $2.8 million recently.
📉 BSN Capital Partners reduced its ISRG position by 41.5%, selling 71,000 shares to hold 100,000 shares valued at $49.6 million.
📈 Norges Bank established a new massive position worth $2.86 billion in the fourth quarter.
🚀 J. Stern & Co. LLP increased its stake by 18,504.6% to own 2.13 million shares valued at $1.2 billion.
📈 Northwestern Mutual Wealth Management raised its holdings by 1,043.3% to acquire an additional 1.22 million shares.
📈 Arrowstreet Capital Limited Partnership increased its position by 95.3% in the first quarter.
📉 Deutsche Bank lowered its price target from $440 to $366 and issued a sell rating.
📉 HSBC downgraded Intuitive Surgical from a buy to a hold with a $391 price objective.
📈 Barclays maintains an overweight rating with a high $651 price target.
📊 The stock currently trades at a PE ratio of 40.47 with a market cap of $124.82 billion.
💼 Insiders sold a total of 6,634 shares valued at $2.8 million over the last ninety days.
Bullish Signals
Norges Bank and J. Stern & Co. increased stakes significantly.
Northwestern Mutual added 1.2M shares, up over 1,000%.
Risk Factors
Deutsche Bank and HSBC downgraded ratings or lowered price targets.
Insiders sold $2.8 million in stock over last 90 days.
Bullish Signals
Major institutional investors like Norges Bank and J. Stern & Co. have significantly increased their stakes, indicating strong confidence in the company's long-term prospects.
Northwestern Mutual Wealth Management added over 1.2 million shares to its portfolio, representing a massive increase of more than 1,000%.
Risk Factors
Deutsche Bank and HSBC have downgraded their ratings or lowered price targets, signaling potential concerns about the current valuation or growth trajectory.
Insiders sold $2.8 million worth of stock in the last ninety days, which can sometimes indicate a lack of immediate confidence at the executive level.
HSBC downgraded Intuitive Surgical (NASDAQ:ISRG) from a Buy to a Hold rating, setting a $391 target price. This move follows a series of recent analyst adjustments, including Sanford Bernstein lowering its target to $685 and Jefferies reducing its objective to $515, though the consensus remains a Moderate Buy with an average target of $509.02.
The company reported strong quarterly financial results on July 16th, beating earnings estimates with $2.80 EPS versus a consensus of $2.48 and revenue of $2.89 billion against expectations of $2.83 billion. Revenue grew 18.4% year-over-year to $2.89 billion, while the business maintained a net margin of 28.45% and a return on equity of 16.91%, demonstrating robust profitability.
Despite positive earnings, insider selling activity was notable in June, with EVP Gary Loeb and SVP Iman Jeddi executing pre-arranged Rule 10b5-1 sales totaling over $2.5 million. Conversely, institutional investors showed significant accumulation in the fourth quarter, with Norges Bank, J. Stern & Co., and Northwestern Mutual increasing their stakes substantially.
Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems, which are deployed in hospitals globally for minimally invasive procedures. The company's business model relies on selling systems, instruments, and proprietary software while providing essential training and servicing support to maintain high margins and recurring revenue streams.
📉 HSBC downgraded stock to Hold with $391 target.
📈 Q2 EPS beat estimates at $2.80 vs $2.48 consensus.
💰 Revenue surged 18.4% YoY to reach $2.89 billion.
🛡️ Net margin remains strong at 28.45%.
🏦 Major institutions increased holdings in Q4.
📉 HSBC downgraded Intuitive Surgical from Buy to Hold with a $391 target price following recent analyst skepticism.
📈 The company beat Q2 earnings estimates significantly, reporting $2.80 EPS compared to the consensus of $2.48.
💰 Revenue reached $2.89 billion for the quarter, representing an 18.4% year-over-year increase.
🛡️ Intuitive Surgical maintained a healthy net margin of 28.45% and a return on equity of 16.91%.
📉 Insider selling occurred in June as EVP Gary Loeb and SVP Iman Jeddi sold shares under pre-arranged trading plans.
🏦 Major institutional investors including Norges Bank and J. Stern & Co. significantly increased their holdings in Q4.
🔬 The firm is best known for its da Vinci surgical systems used for minimally invasive procedures globally.
📊 Analyst consensus remains Moderate Buy with an average price target of $509.02 despite recent downgrades.
Bullish Signals
Revenue hit $2.89B, beating estimates of $2.83B.
EPS reached $2.80, surpassing the $2.48 consensus.
HSBC downgraded stock to Hold with lowered $391 target.
Analysts Bernstein and Jefferies reduced targets to $685 and $515.
Insiders sold 6,634 shares worth $2.79 million last quarter.
Bullish Signals
Intuitive Surgical reported quarterly revenue of $2.89 billion, surpassing analyst estimates of $2.83 billion by a notable margin.
The company achieved an EPS of $2.80, beating the consensus estimate of $2.48 by $0.32, indicating strong operational execution.
Revenue grew 18.4% year-over-year, demonstrating continued market expansion and demand for robotic surgical systems.
Net margins remained robust at 28.45%, reflecting the company's high-margin business model and pricing power.
Return on equity stood at 16.91%, highlighting efficient capital deployment and strong shareholder value generation.
Significant institutional accumulation occurred in Q4, with Norges Bank purchasing a stake worth approximately $2.86 billion.
Risk Factors
HSBC downgraded the stock from Buy to Hold, citing concerns that may be reflected in their lowered $391 target price.
Multiple other analysts recently reduced price targets, including Sanford Bernstein dropping its target to $685 and Jefferies to $515.
Corporate insiders sold a total of 6,634 shares worth $2.79 million in the last quarter, signaling potential lack of confidence at the executive level.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
